- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Temozolomide safe in patients with renal dysfunction, study claims
USA: Patients with severe renal impairment, defined as an eGFR < 36 mL/min/1.73m2, experience hematologic toxicity comparable to that of patients with normal renal function, says an article published in the Journal of Neuro-Oncology.
The major chemotherapy agent used to treat high grade astrocytoma is temozolomide (TMZ), a cytotoxic DNA alkylating agent. Since methylhydrazine, the primary alkylator, is not recovered in urine, renal function is not anticipated to have an impact on clearance. According to the TMZ prescribing instructions, people with impaired renal function (eGFR 36 mL/min/1.73 m2) have not had their pharmacokinetics examined. In order to assess the safety of delivering TMZ at full dosage, Kayla Garzio and team reviewed clinical data with TMZ in patients with compromised renal function.
This study's main goal was to describe the frequency and severity of thrombocytopenia in people who received TMZ for high-grade gliomas (HGG) or primary CNS lymphomas (PCNSL) and had eGFR levels below < 60/min/1.73 m2. The frequency and intensity of neutropenia, lymphopenia hepatotoxicity, and the total number of TMZ cycles were secondary objectives. To find instances for this investigation, medical records of patients with HGG or PCNSL treated with TMZ between October 1, 2016, and September 30, 2019 were obtained.
The key findings of this study were:
1. For this study, 32 patients were eligible. 38/39 cycles (97%) of the seven patients with eGFR < 36 mL/min/1.73m2 were finished without grade 3–4 thrombocytopenia.
2. Grade 3-4 lymphopenia occurred in 5 cycles (15%) while grade 3-4 neutropenia occurred in no individuals.
3. One patient stopped taking TMZ seven days before the end of the radiation treatment because of thrombocytopenia.
In conclusion, due to a paucity of information and cautions against usage in the package insert, it may have been previously advised, restricted, or avoided to administer TMZ to this patient population. Our institution's experience suggests that individuals with eGFR < 36 mL/min/1.73m2 can receive TMZ with a side effect profile that is comparable to that of people without renal impairment. However, it is suggested that blood counts and chemistries be monitored cautiously.
Reference:
Garzio, K., McElroy, K., Grossman, S., Holdhoff, M., Ozer, B., & Yankulina, O. (2022). Safety of temozolomide use in adult patients with renal dysfunction. In Journal of Neuro-Oncology. Springer Science and Business Media LLC. https://doi.org/10.1007/s11060-022-04098-1
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751